User profiles for Hertzel C. Gerstein
 | Hertzel GersteinMcMaster University Verified email at mcmaster.ca Cited by 125284 |
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
HC Gerstein, JFE Mann, Q Yi, B Zinman, SF Dinneen… - Jama, 2001 - jamanetwork.com
ContextMicroalbuminuria is a risk factor for cardiovascular (CV) events. The relationship
between the degree of albuminuria and CV risk is unclear.ObjectivesTo estimate the risk of CV …
between the degree of albuminuria and CV risk is unclear.ObjectivesTo estimate the risk of CV …
[HTML][HTML] Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events …
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events …
Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview
SE Capes, D Hunt, K Malmberg, HC Gerstein - The Lancet, 2000 - thelancet.com
Background High blood glucose concentration may increase risk of death and poor outcome
after acute myocardial infarction. We did a systematic review and metaanalysis to assess …
after acute myocardial infarction. We did a systematic review and metaanalysis to assess …
[HTML][HTML] Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
…, R Diaz, K Dickstein, HC Gerstein… - … England Journal of …, 2015 - Mass Medical Soc
Background Cardiovascular morbidity and mortality are higher among patients with type 2
diabetes, particularly those with concomitant cardiovascular diseases, than in most other …
diabetes, particularly those with concomitant cardiovascular diseases, than in most other …
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for …
OBJECTIVE: To assess the relationship between nondiabetic glucose levels and cardio
vascular risk. RESEARCH DESIGN AND METHODS: Three independent searches using …
vascular risk. RESEARCH DESIGN AND METHODS: Three independent searches using …
Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview
SE Capes, D Hunt, K Malmberg, P Pathak, HC Gerstein - Stroke, 2001 - Am Heart Assoc
Background and Purpose “Stress” hyperglycemia may be associated with increased mortality
and poor recovery in diabetic and nondiabetic patients after stroke. A systematic review …
and poor recovery in diabetic and nondiabetic patients after stroke. A systematic review …
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz… - The Lancet, 2019 - thelancet.com
Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes …
…, NG Clark, F Costa, R Eckel, V Fonseca, HC Gerstein… - Circulation, 2007 - Am Heart Assoc
The American Heart Association (AHA) and the American Diabetes Association (ADA) have
each published guidelines for cardiovascular disease prevention: The ADA has issued …
each published guidelines for cardiovascular disease prevention: The ADA has issued …
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial
Background: The cardiovascular risk associated with early renal insufficiency is unknown.
Clinicians are often reluctant to use angiotensin-converting enzyme inhibitors in patients with …
Clinicians are often reluctant to use angiotensin-converting enzyme inhibitors in patients with …
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised …
Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
